NEW ORLEANS — Patients who took dual antiplatelet therapy after PCI for a shorter amount of time while continuing P2Y12 inhibitor monotherapy did not have an increased risk for MI, death or stroke compared with those who took standard therapy for 1 year, according to data from two studies presented at the American College of Cardiology Scientific Session.
This activity is supported by an independent educational grant from Amarin Pharma Inc.
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2019 Healio All Rights Reserved.